Potent and specific inhibitor of phospholipase D1 (PLD1) in cellular (PLD1 IC50 = 11nM Calu-1 cells; PLD2 IC50 = 1800nM HEK293-gfpPLD2 cells) and in vitro (hPLD1 IC50 = 46nM; hPLD2 IC50 = 933nM) assays. Significantly decreases invasive migration in breast cancer cell lines (MDA-231, 4T1 and PMT).
Product Details
| Alternative Name: | N-[(2S)-1-[4-(5-Chloro-2-oxo-3H-benzimidazol-1-yl)-piperidin-1-yl]-propan-2-yl]naphthalene-2-carboxamide |
| |
| Formula: | C26H27ClN4O2 |
| |
| MW: | 463.0 |
| |
| CAS: | 1130067-06-9 |
| |
| Purity: | ≥98% (TLC) |
| |
| Appearance: | Pale-yellow solid. |
| |
| Solubility: | Soluble in DMSO (>25mg/ml) or 100% ethanol (>25mg/ml). |
| |
| Shipping: | Blue Ice |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Store solutions at -20°C for up to 3 months. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness: S.A. Scott, et al.; Nat. Chem. Biol.
5, 108 (2009),
Abstract;
